Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 11.58% from its latest closing price compared to the recent 1-year high of $33.98. The company’s stock price has collected 41.48% of gains in the last five trading sessions. Press Release reported on 01/08/21 that Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer
Is It Worth Investing in Pacific Biosciences of California Inc. (NASDAQ :PACB) Right Now?
Plus, the 36-month beta value for PACB is at 1.24. Opinions of the stock are interesting as 2 analysts out of 5 who provided ratings for Pacific Biosciences of California Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $22.20, which is -$18.3 below the current price. PACB currently public float of 178.29M and currently shorts hold a 6.70% ratio of that float. Today, the average trading volume of PACB was 4.75M shares.
PACB’s Market Performance
PACB stocks went up by 41.48% for the week, with a monthly jump of 62.97% and a quarterly performance of 188.30%, while its annual performance rate touched 690.10%. The volatility ratio for the week stands at 13.51% while the volatility levels for the past 30 days are set at 11.61% for Pacific Biosciences of California Inc.. The simple moving average for the period of the last 20 days is 48.97% for PACB stocks with a simple moving average of 307.29% for the last 200 days.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Piper Sandler repeating the rating for PACB by listing it as a “Neutral.” The predicted price for PACB in the upcoming period, according to Piper Sandler is $12 based on the research report published on November 03rd of the previous year 2020.
JP Morgan, on the other hand, stated in their research note that they expect to see PACB reach a price target of $15. The rating they have provided for PACB stocks is “Overweight” according to the report published on October 02nd, 2020.
Morgan Stanley gave a rating of “Equal-Weight” to PACB, setting the target price at $7 in the report published on September 09th of the previous year.
PACB Trading at 90.24% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 8.00% of gains for the given period.
Volatility was left at 11.61%, however, over the last 30 days, the volatility rate increased by 13.51%, as shares surge +74.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +150.68% upper at present.
During the last 5 trading sessions, PACB rose by +41.48%, which changed the moving average for the period of 200-days by +1,072.52% in comparison to the 20-day moving average, which settled at $25.42. In addition, Pacific Biosciences of California Inc. saw 41.48% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PACB starting from Hunkapiller Michael, who sale 364,451 shares at the price of $25.62 back on Dec 22. After this action, Hunkapiller Michael now owns 898,215 shares of Pacific Biosciences of California Inc., valued at $9,335,716 using the latest closing price.
Hunkapiller Michael, the Director of Pacific Biosciences of California Inc., sale 335,549 shares at $23.00 during a trade that took place back on Dec 21, which means that Hunkapiller Michael is holding 898,215 shares at $7,718,327 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -110.62 for the present operating margin
- +38.04 for the gross margin
The net margin for Pacific Biosciences of California Inc. stands at -92.57. The total capital return value is set at -81.97, while invested capital returns managed to touch -74.59. Equity return is now at value -63.80, with -20.40 for asset returns.
Based on Pacific Biosciences of California Inc. (PACB), the company’s capital structure generated 112.30 points at debt to equity in total, while total debt to capital is 52.90. Total debt to assets is 41.67, with long-term debt to equity ratio resting at 76.41. Finally, the long-term debt to capital ratio is 35.99.
When we switch over and look at the enterprise to sales, we see a ratio of 8.76, with the company’s debt to enterprise value settled at 0.08. The receivables turnover for the company is 7.62 and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.